Introduction
Mantle cell lymphoma (MCL) is now acknowledged to be an entity, including the previously-designated centrocytic or diffuse small cleaved cell lymphomas, with distinct immunophenotypic and genetic features [1, 2] . Typically, MCL tumor cells show a high expression of IgM, IgD and CD20 and a low expression of CD5, while there is usually no expression of CD10 and CD23 [3] . The most consistent abnormality is a t(ll;14) translocation typically found in 70% of cases [4] which results in overexpression of the 6c/-1 gene.
The natural history of MCL shows continuous progression toward increased malignancy, even though a true histological transformation is a rare event [5] . Prognosis is poor, with a median survival of three to four years [5] [6] [7] [8] . Despite further illumination of the disease, the therapeutic options remain unclear [9] . The role of anthracycline-containing regimens is still controversial [7, 10] , but an advantage for a CHOP-like aggressive chemotherapy has recently been suggested [8] . Other studies have demonstrated that the only important parameter associated with a longer survival is achievement of complete remission (CR) [8, 10, 11] . These results suggest a role for high-dose therapy with stem cell rescue, and recent reports with a few patients seem encouraging [12, 13] . We report here our experience from 1989 to 1996 with 16 MCL patients receiving high-dose chemotherapy and autologous stem cell rescue.
Patients and methods

Patients
Between August 1989 and February 1996, 16 patients (Table 1) with MCL were treated with high-dose chemotherapy and autologous stem cell rescue in our department. Histological diagnoses were reviewed (FB, PF) in accord with the R.E.A.L. Classification definitions.
Patients were selected for high-dose chemotherapy because of first treatment line failure (refractoriness or relapse), or because of two or three unfavorable-prognosis criteria according to the age-adjusted International Prognosis Index (IP!) at diagnosis [14] , One patient with one IPI criteria received high-dose treatment while in partial remission (PR) after undergoing the CHOP regimen. All patients had complete tumor restaging, including bone marrow (BM) examination, shortly before intensive therapy (Table 2 ). Five patients were in CR, three having been treated in first relapse, one in first-line and one in second Abbreviations: BM -bone marrow; GI -gastro-intestinal; IPIInternational Prognostic Index. " Generalized lymphadenopathy = disease involving both sides of the diaphragm and > 3 lymph nodes area.
relapse. Five of the 11 PR patients were intensified in first PR and six after responding to salvage regimens.
Treatment
During the seven years of this study, induction chemotherapy varied but all patients received at least one anthracydine-containing regimen. The source of the stem cells and the conditioning regimen were uniform: the patient treated in 1989 was transplanted with bone marrow, while all others received peripheral blood stem cells (PBSC), in one case combined with bone marrow. PBSC mobilisation was performed with chemotherapy (cyclophosphamide 5,25 g/m 2 or 4,5 g/m 2 plus etoposide 450 mg/m 2 ) followed by growth factors in 11 cases. The conditioning regimen consisted of cyclophosphamide plus etoposide and fractionated total body irradiation (10 Gy over three days) in 12 patients, BEAM (BCNU, etoposide, aracytine, melphalan) in three patients, while one patient received cyclophosphamide, etoposide and BCNU (CBV).
Response
Three months after intensification, the treatment response was evaluated by clinical examination, computerized tomography (CT) scan, bone marrow aspirate and biopsy. CR was defined as the disappearance of disease in all sites, including bone marrow. PR was defined as a reduction of more than 50% in the product of the two largest diameters of each measurable lesion, or as the persistence of bone marrow infiltration as the only residual site of disease.
Statistical methods
OveraU survival (OS) was defined as the time from reinfusion of PBSC until death or date of last visit. Freedom from progression (FFP) was defined as the time from reinfusion of PBSC to the time of disease progression. Event-free survival (EFS) was defined as the time from reinfusion of PBSC to the time of first event, whether progression or treatment-related death. Survival distributions were estimated by the Kaplan-Meyer product-limit method [15] , and observed differences were assessed using the log-rank test.
Results
Population treated
The median number of chemotherapy regimens administered before conditioning treatment was 2 (1-4). Six patients were intensified at first-line therapy, nine after a first relapse and one after the second relapse. The median time between diagnosis and transplant was 18 months (4-36). Disease status before high-dose chemotherapy was CR in five patients and PR in 11, of whom nine had persisting marrow infiltration at the time of the PBSC collection ( Table 2 ). The median number of reinfused MNC was 2.58 x 10 8 /kg (0.83-11.6). The median count of CFU-GM was 4.46 x 10 4 /kg (2.55-298). The amount of CD34+ cells (six patients) reached a median of 6.0 x 10 6 /kg (0.7-44). After bone marrow or PBSC reinfusion (day 0), the median time to achievement of a PN count > 0.5 G/l and > 1 G/l were, respectively, 12 (10-29) and 13 (10-35) days, but two patients died before neutrophil recovery of bleeding complications. The median time to attainment of an unsupported platelet count ^ 20 G/l for 12 evaluable patients was 10 (7-34) days. The two patients who presented toxic death did not reach this count, and two further patients remained dependent on platelet transfusions for several months.
Toxicity and results of treatments
Two patients treated in 1991 died early, on days 19 and 40, of toxic effects, one of diffuse and irreversible intraalveolary haemorrhage during undocumented infection, and the other of uncontrolled intravesical bleeding. A third patient who still required platelet transfusions three months after transplant died on day 97 of intracerebral bleeding. These three patients in first relapse had been heavily pretreated at the time of the conditioning regimen. Except for the two early deaths, the median time of hospitalisation after transplant was 18 days (12-41).
Other relevant toxicities were grade 3 infection in five patients and grade 3 hepatic toxicity in one patient. Grade 3-4 digestive toxicity and mucositis occurred, respectively, in two and five patients. Three months after transplant, seven patients were in CR and two in PR, two were stable and two had progressed. Of the seven patients who achieved CR, four relapsed at 11, 13, 15 and 17 months after intensive therapy, and three have died. The two patients in PR because of persisting BM infiltration were treated with interferon-a and remained in continuous PR 9+ and 6+ months after transplant. With a median follow-up of 22 months (12-90), only five patients are now alive without progression, three of them in CR. The median times of event-free survival (EFS) and overall survival (OS) were, respectively, 249 and 317 days (Figure 1) . Excluding the three treatment-related deaths, the median time of freedom-from-progression (FFP) was 288 days. The expected three-year OS and EFS were, respectively, 24% ± 13% and 24% ± 12%. The median OS after diagnosis was 29 months. Considering different parameters before high-dose chemotherapy, neither disease status at transplant (PR versus CR), number of previous treatment before intensification, nor persistence of BM infiltration at harvest could be identified as having significantly influenced outcome after transplant. A longer but not statistically significantly different survival was observed in patients intensified in first PR or CR (Figure 2 ) and in those intensified during the first year after diagnosis than in patients intensified after progression or after more than one year of follow-up (P = 0.14 and 0.24, respectively).
Discussion
The results of this study analyzing 16 MCL-intensified patients are disappointing and fail to compare favorably with the outcome observed with standard chemotherapy [7] [8] [9] . Few studies had explored the existence of a doseresponse relationship and the possible benefit of highdose chemotherapy in MCL. Stewart et al. reported the intensification of nine MCL patients, and suggested that high-dose treatment could yield benefit if delivered early in the disease [12] . Recently, Haas et al. reported 13 patients who show a very favorable outcome, with a disease-free survival of 76% and an overall survival of 92% [13] .
In the present study, we were not able to confirm those good results. One of the reasons may be that nine of 13 patients (69%) in the Haas study were in first remission as compared to six of 16 (38%) in our series. The importance of this point is suggested in Figure 2 , which shows a better outcome for patients intensified in first remission. Secondly, the median time from diagnosis to intensive treatment in the Haas study was 12 months compared to 18 months in our trial. The patients in our study who were intensified less than one year after initial diagnosis tend to have better outcomes. However, this apparent benefit of early intensification may only reflect the natural history of the disease.
Moreover, CR before high-dose therapy has been obtained in only five (31%) cases in the present trial, compared with eight (62%) in the Haas study. Intensification has made possible the achievement of two further CR in our group of patients. Of the six patients who were not in CR after transplant, five had persisting BM infiltration as the only site of disease. However, we must note that two of the three patients alive in CR showed minimal but persistent BM infiltration before undergoing the high-dose conditioning regimen. Achievement of CR in the bone marrow is certainly an important factor in longer survival, and indicates that a small infiltration does not preclude intensification.
Finally, we cannot rule out that the dose of the TBI administered (14.4 Gy in the Haas study compared with 10 Gy in our study) could also be a reason for the difference observed between the results of these two trials.
We were not able to establish, on the basis of this trial, a benefit for intensive chemotherapy for MCL patients. However, in view of these results and others, this approach could be beneficial for some patients. In this hypothesis, it is possible that intensification in firstline and a short delay between lymphoma diagnosis and transplant, could represent important criteria, whereas intensification is probably not beneficial after relapse.
